Given the high significance of IDH mutation and 1p/19q codeletion in the clinical management of gliomas [14], it would be valuable to examine the performance of the 2HG‐tailored long‐TE PRESS sequence for evaluating cystathionine and 2HG in a cohort of glioma patients and subsequently 1p/19q and IDH status. This evidence concerns the gene IDH1 and central nervous system cancer.